Discovery of fruquintinib, a potent and highly selective small molecule inhibitor of VEGFR 1, 2, 3 tyrosine kinases for cancer therapy

Preclinical pharmacokinetics and disposition of a novel selective VEGFR inhibitor Fruquintinib (HMPL-013) and the prediction of its human pharmacokinetics

(2014) Yi Gu et al.   CANCER CHEMOTHERAPY AND PHARMACOLOGY

Abstract 2413: Phase I study of safety and pharmacokinetics of fruquintinib, a selective inhibitor of VEGF receptor-1, -2, and -3 tyrosine kinases in patients with advanced solid tumors.

(2014) Jin Li et al.   CANCER RESEARCH

Regorafenib in metastatic colorectal cancer

(2014) Andrea Sartore-Bianchi et al.   Expert Review of Anticancer Therapy

MT1-MMP in breast cancer: induction of VEGF-C correlates with metastasis and poor prognosis

(2013) Guangyu Yao et al.   Cancer Cell International

p53 promotes VEGF expression and angiogenesis in the absence of an intact p21-Rb pathway

(2013) M Farhang Ghahremani et al.   CELL DEATH AND DIFFERENTIATION

Safety and efficacy of first-line bevacizumab combination therapy in Chinese population with advanced non-squamous NSCLC: data of subgroup analyses from MO19390 (SAiL) study

(2013) C. C. Zhou et al.   Clinical & Translational Oncology

Tumor VEGF:VEGFR2 autocrine feed-forward loop triggers angiogenesis in lung cancer

(2013) Sampurna Chatterjee et al.   JOURNAL OF CLINICAL INVESTIGATION

A phase II study of erlotinib in combination with bevacizumab versus chemotherapy plus bevacizumab in the first-line treatment of advanced non-squamous non-small cell lung cancer

(2013) T. Ciuleanu et al.   LUNG CANCER

Hypoxia-driven osteopontin contributes to breast tumor growth through modulation of HIF1α-mediated VEGF-dependent angiogenesis

(2013) R Raja et al.   ONCOGENE

Vascular endothelial growth factor (VEGF) expression in locally advanced prostate cancer: secondary analysis of radiation therapy oncology group (RTOG) 8610

(2013) Larry Pan et al.   Radiation Oncology

VEGF-c expression in an in vivo model of orthotopic endometrial cancer and retroperitoneal lymph node metastasis

(2013) Yong-Wen Huang et al.   Reproductive Biology and Endocrinology

Development and strategies of VEGFR-2/KDR inhibitors

(2012) Lingyi Huang et al.   Future Medicinal Chemistry

Concise Drug Review: Pazopanib and Axitinib

(2012) R. M. J. M. van Geel et al.   ONCOLOGIST

Microvessel density and VEGF, HIF-1α expression in primary oral melanoma: correlation with prognosis

(2012) O Simonetti et al.   ORAL DISEASES

Signal transduction by vascular endothelial growth factor receptors

(2011) Sina Koch et al.   BIOCHEMICAL JOURNAL

Vascular Endothelial Growth Factor (VEGF), VEGF Receptors and Their Inhibitors for Antiangiogenic Tumor Therapy

(2011) Satoru Takahashi   BIOLOGICAL & PHARMACEUTICAL BULLETIN

A phase II study of bevacizumab, oxaliplatin, and docetaxel in locally advanced and metastatic gastric and gastroesophageal junction cancers

(2010) B. F. El-Rayes et al.   ANNALS OF ONCOLOGY

Lymphangiogenesis and cancer metastasis

(2010) Mahir et al.   Frontiers in Bioscience-Landmark

Tumour vascularization via endothelial differentiation of glioblastoma stem-like cells

(2010) Lucia Ricci-Vitiani et al.   NATURE

Sorafenib

(2009) Gillian M. Keating et al.   DRUGS

VEGF-A and i-NOS expression are prognostic factors in serous epithelial ovarian carcinomas after complete surgical resection

(2009) K Engels et al.   JOURNAL OF CLINICAL PATHOLOGY

Capecitabine and irinotecan with and without bevacizumab for advanced colorectal cancer patients

(2009) Markus Moehler et al.   WORLD JOURNAL OF GASTROENTEROLOGY

Tumor Angiogenesis

(2008) Robert S. Kerbel   NEW ENGLAND JOURNAL OF MEDICINE